The new version of the medical insurance catalog implements three PD-1 prices, and the annual fee of Hengrui Erica is less than 10,000

On March 1, 2021, the latest version of the National Medical Insurance Drug List was officially launched.

Since the company signed a confidentiality agreement with the Medical Insurance Bureau, the negotiated price of the drug was not disclosed to the public for the first time.

Three domestically produced PD-1 medical insurance prices have been exposed one after another

The price war has started quietly

In the 2020 medical insurance negotiations, all three domestically produced PD-1 products were successfully negotiated and entered the medical insurance catalog.

According to reliable news today, the unit price of Hengrui Medicine's Karelizumab (trade name: Erica) after medical insurance is 2928 yuan/200mg, and the cost after a single medical insurance is only less than 600 yuan.

Taking the approved indications for lung cancer and liver cancer as examples, the reimbursement ratio is calculated at 80% (specifically subject to the local urban medical insurance policy).

It is also understood that the new price of BeiGene’s PD-1 tislelizumab (trade name: Beizian) before medical insurance reimbursement has dropped to 2180 yuan per tube, a drop of up to 80%, and the annual treatment cost is only less than 7.

Recently, BeiGene announced its full-year financial results for 2020, with annual revenue of US$308.

Last year, Junshi Biologics’ PD-1 negotiation video was recognized by the industry, and the price of its teriprolizumab (trade name: Tuoyi) per bottle (specification: 80mg) was alleged to be 906.

Among the PD-1 monoclonal antibodies currently in the medical insurance catalogue, Cinda Biologics has only one medical insurance reimbursement indication-relapsed/refractory classic Hodgkin's lymphoma.

Cinda Bio's Sintilizumab has been on the market since March 2019, with sales of 1.

After the domestic PD-1 product successfully entered the medical insurance catalogue and the negotiated price was lower, on December 31, 2020, Cinda Biotech joined hands with Beijing Kangmeng to launch the PD-1 product Daboshu "First Round 2+" 2.

Many new indications for PD-1 have been approved, and the tide of going out to sea is rising

The PD-1 price battlefield is full of smoke, and various indications are also constantly working hard.

In January 2021, BeiGene's third indication of tislelizumab was approved for the first-line treatment of locally advanced or metastatic squamous non-small cell lung cancer in combination with paclitaxel + carboplatin, becoming the first approved in my country Domestic PD-1 monoclonal antibody for the first-line indication of lung squamous cell carcinoma.

On February 3, Cinda Biotech and Eli Lilly announced that the PD-1 inhibitor Sintilimab injection jointly developed by the two parties was officially approved by the National Food and Drug Administration, combined with pemetrexed and platinum-based chemotherapy for non-squamous use.

On February 19th, Junshi Biologics issued an announcement stating that it had recently received approval from the National Medical Products Administration for its self-developed anti-PD-1 monoclonal anti-tumor drug teriprizumab injection for use in previous second-line and above Treatment of patients with recurrent/metastatic nasopharyngeal carcinoma (NPC) who have failed systemic therapy.

According to statistics from Southwest Securities, domestic PD-1 monoclonal antibodies are in a state of intensive research and development.

As the domestic PD-1 market competition is further fierce, domestic monoclonal antibodies all choose to go overseas.
Among them, BeiGene authorized the rights and interests of most countries in Europe and the United States to Novartis, involving an amount of US$2.
2 billion down payment/milestone payment + royalties of 20%-30% of net sales, setting the current record for the highest authorized transaction amount of a single drug in China .

On March 1, Junshi Biotech and AstraZeneca signed the "Exclusive Promotion Agreement.
" According to the promotion agreement, Junshi Biotech will grant AstraZeneca Pharmaceuticals the exclusive right to promote the indications in the field of urinary oncology, which are subsequently approved for marketing in mainland China, and all the approved indications are in non-core cities.
Exclusive promotion rights for the region.
The company will continue to be responsible for the promotion of other approved indications in core urban areas except for indications in the field of urinary oncology.

Southwest Securities pointed out that in the current price decline, the development of overseas equity lisence out may be a better way out.
And pharmaceutical companies can also use the partners' mature overseas sales channels to have the opportunity to share the global PD-1 monoclonal antibody market.

The new version of the National Medical Insurance Catalogue will be officially launched nationwide from March 1, 2021.
Attachment: Information on 96 products transferred through negotiation, and 72 types of announced drug price declines, as well as information on some renewed products and updated prices of 6 renewed products.
Source: Medical Rubik's Cube.